Acro Biomedical
Market Cap
US$181.5m
Last Updated
2019/10/15 00:23 UTC
Data Sources
Company Financials
Executive Summary
Acro Biomedical Co., Ltd. develops and markets nutritional products.
Snowflake
Fundamentals
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Acro Biomedical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-9.5%
ACBM
-0.08%
US Healthcare
1.3%
US Market
1 Year Return
22.6%
ACBM
-10.6%
US Healthcare
5.9%
US Market
Return vs Industry: ACBM exceeded the US Healthcare industry which returned -10.6% over the past year.
Return vs Market: ACBM exceeded the US Market which returned 5.9% over the past year.
Shareholder returns
| ACBM | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.5% | -0.08% | 1.3% |
| 30 Day | -22.4% | -4.1% | -1.9% |
| 90 Day | -31.5% | -9.4% | -1.8% |
| 1 Year | 22.6%22.6% | -9.2%-10.6% | 8.3%5.9% |
| 3 Year | n/a | 28.9%23.7% | 45.6%36.2% |
| 5 Year | n/a | 58.9%49.4% | 66.1%47.9% |
Price Volatility Vs. Market
How volatile is Acro Biomedical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Acro Biomedical undervalued compared to its fair value and its price relative to the market?
191.45x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: ACBM ($3.8) is trading above our estimate of fair value ($0.01)
Significantly Undervalued: ACBM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ACBM is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.
PE vs Market: ACBM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate ACBM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACBM is overvalued based on its PB Ratio (191.4x) compared to the US Healthcare industry average (2.4x).
Next Steps
Future Growth
How is Acro Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
11.0%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Acro Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Acro Biomedical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Acro Biomedical's filings and announcements here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Acro Biomedical performed over the past 5 years?
56.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: ACBM is unprofitable, but has reduced losses over the past 5 years at a rate of 56.6% per year.
Accelerating Growth: Unable to compare ACBM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACBM is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).
Return on Equity
High ROE: ACBM has a negative Return on Equity (-14.97%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: ACBM is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: ACBM is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Acro Biomedical's financial position?
Financial Position Analysis
Short Term Liabilities: ACBM's short term assets ($1.1M) exceeds its short term liabilities ($133.1K)
Long Term Liabilities: ACBM has no long term liabilities
Debt to Equity History and Analysis
Debt Level: ACBM's debt to equity ratio (10.9%) is considered satisfactory
Reducing Debt: Insufficient data to determine if ACBM's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ACBM's debt is well covered by operating cash flow (31.6%).
Interest Coverage: Insufficient data to determine if ACBM's interest payments on its debt are well covered by EBIT.
Balance Sheet
Inventory Level: ACBM has a high level of physical assets or inventory.
Debt Coverage by Assets: ACBM's debt is covered by short term assets (assets are 10.359890x debt).
Next Steps
Dividend
What is Acro Biomedical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate ACBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ACBM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if ACBM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACBM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACBM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Acro Biomedical's salary, the management and board of directors tenure and is there insider trading?
CEO
Pao-Chi Chu (65yo)
2.8yrs
Tenure
Mr. Pao-Chi Chu has been Chief Executive Officer, President, Chief Financial Officer, Secretary and Director of Acro Biomedical Co., Ltd. since January 30, 2017. Mr. Chu has served as the chairman of Mucho ...
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Pao-Chi Chu (65yo)
CEO, CFO
- Tenure: 2.8yrs
Board Members
Pao-Chi Chu (65yo)
CEO, CFO
- Tenure: 2.8yrs
Company Information
Acro Biomedical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Acro Biomedical Co., Ltd.
- Ticker: ACBM
- Exchange: OTCPK
- Founded: 2014
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: US$181.488m
- Shares outstanding: 47.76m
- Website: https://www.acrobiomedicalco.com
Location
- Acro Biomedical Co., Ltd.
- 2175 Visionary Way
- Suite 1160
- Fishers
- Indiana
- 46038
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ACBM | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Jul 2016 |
Biography
Acro Biomedical Co., Ltd. develops and markets nutritional products. It sells cordycepin and cordyceps powder, a fungus used in traditional Chinese medicine; and metallothionein MT-3 elizer, a protein powd ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/15 00:23 |
| End of Day Share Price | 2019/10/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.